S&P 500   3,750.85 (-0.86%)
DOW   29,953.49 (-1.06%)
QQQ   280.56 (-0.50%)
AAPL   145.54 (-0.59%)
MSFT   247.33 (-0.75%)
META   139.48 (+0.36%)
GOOGL   101.56 (+0.13%)
AMZN   120.58 (-0.31%)
TSLA   239.65 (-0.48%)
NVDA   131.72 (-0.28%)
NIO   14.94 (-6.86%)
BABA   84.58 (+0.23%)
AMD   68.16 (+0.32%)
T   15.39 (-3.39%)
MU   54.75 (+0.04%)
CGC   3.53 (+14.98%)
F   12.37 (-1.12%)
GE   66.13 (-1.94%)
DIS   100.14 (-0.65%)
AMC   7.24 (-1.23%)
PYPL   94.44 (+0.65%)
PFE   43.15 (-2.20%)
NFLX   240.72 (+1.69%)
S&P 500   3,750.85 (-0.86%)
DOW   29,953.49 (-1.06%)
QQQ   280.56 (-0.50%)
AAPL   145.54 (-0.59%)
MSFT   247.33 (-0.75%)
META   139.48 (+0.36%)
GOOGL   101.56 (+0.13%)
AMZN   120.58 (-0.31%)
TSLA   239.65 (-0.48%)
NVDA   131.72 (-0.28%)
NIO   14.94 (-6.86%)
BABA   84.58 (+0.23%)
AMD   68.16 (+0.32%)
T   15.39 (-3.39%)
MU   54.75 (+0.04%)
CGC   3.53 (+14.98%)
F   12.37 (-1.12%)
GE   66.13 (-1.94%)
DIS   100.14 (-0.65%)
AMC   7.24 (-1.23%)
PYPL   94.44 (+0.65%)
PFE   43.15 (-2.20%)
NFLX   240.72 (+1.69%)
S&P 500   3,750.85 (-0.86%)
DOW   29,953.49 (-1.06%)
QQQ   280.56 (-0.50%)
AAPL   145.54 (-0.59%)
MSFT   247.33 (-0.75%)
META   139.48 (+0.36%)
GOOGL   101.56 (+0.13%)
AMZN   120.58 (-0.31%)
TSLA   239.65 (-0.48%)
NVDA   131.72 (-0.28%)
NIO   14.94 (-6.86%)
BABA   84.58 (+0.23%)
AMD   68.16 (+0.32%)
T   15.39 (-3.39%)
MU   54.75 (+0.04%)
CGC   3.53 (+14.98%)
F   12.37 (-1.12%)
GE   66.13 (-1.94%)
DIS   100.14 (-0.65%)
AMC   7.24 (-1.23%)
PYPL   94.44 (+0.65%)
PFE   43.15 (-2.20%)
NFLX   240.72 (+1.69%)
S&P 500   3,750.85 (-0.86%)
DOW   29,953.49 (-1.06%)
QQQ   280.56 (-0.50%)
AAPL   145.54 (-0.59%)
MSFT   247.33 (-0.75%)
META   139.48 (+0.36%)
GOOGL   101.56 (+0.13%)
AMZN   120.58 (-0.31%)
TSLA   239.65 (-0.48%)
NVDA   131.72 (-0.28%)
NIO   14.94 (-6.86%)
BABA   84.58 (+0.23%)
AMD   68.16 (+0.32%)
T   15.39 (-3.39%)
MU   54.75 (+0.04%)
CGC   3.53 (+14.98%)
F   12.37 (-1.12%)
GE   66.13 (-1.94%)
DIS   100.14 (-0.65%)
AMC   7.24 (-1.23%)
PYPL   94.44 (+0.65%)
PFE   43.15 (-2.20%)
NFLX   240.72 (+1.69%)
NASDAQ:ASND

Ascendis Pharma A/S - ASND Stock Forecast, Price & News

$113.64
+0.18 (+0.16%)
(As of 10/6/2022 03:27 PM ET)
Add
Compare
Today's Range
$109.35
$113.96
50-Day Range
$84.03
$113.46
52-Week Range
$61.58
$172.65
Volume
40,303 shs
Average Volume
505,254 shs
Market Capitalization
$6.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$153.70

Ascendis Pharma A/S MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.91 Rating Score
Upside/​Downside
39.2% Upside
$153.70 Price Target
Short Interest
Bearish
14.89% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.67mentions of Ascendis Pharma A/S in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($8.68) to ($9.55) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

779th out of 1,072 stocks

Pharmaceutical Preparations Industry

382nd out of 534 stocks

ASND stock logo

About Ascendis Pharma A/S (NASDAQ:ASND) Stock

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Receive ASND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

ASND Stock News Headlines

Ascendis Pharma: TransCon CNP Data Coming Q4
Ascendis Pharma A/S (ASND)
Ascendis Pharma (NASDAQ:ASND) Is Using Debt Safely
What 14 Analyst Ratings Have To Say About Ascendis Pharma
See More Headlines
Receive ASND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

ASND Company Calendar

Last Earnings
8/10/2022
Today
10/06/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ASND
Employees
639
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$153.70
High Stock Price Forecast
$180.00
Low Stock Price Forecast
$117.00
Forecasted Upside/Downside
+35.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
11 Analysts

Profitability

Net Income
$-453,810,000.00
Net Margins
-2,099.51%
Pretax Margin
-2,103.78%

Debt

Sales & Book Value

Annual Sales
$9.20 million
Book Value
$18.38 per share

Miscellaneous

Free Float
34,179,000
Market Cap
$6.47 billion
Optionable
Optionable
Beta
0.52

Key Executives

  • Mr. Jan Moller Mikkelsen (Age 62)
    Pres, CEO, Member of Exec. Board & Exec. Director
  • Mr. Michael Wolff Jensen L.L.M. (Age 51)
    Sr. VP, Chief Legal Officer & Member of the Exec. Board
  • Dr. Birgitte Volck M.D. (Age 60)
    Ph.D., Sr. VP and Head of Clinical Devel. & Endocrinology Rare Diseases Medical Affairs
    Comp: $23.04k
  • Mr. Scott T. Smith (Age 48)
    CFO, Sr. VP & Member of Exec. Board
  • Ms. Lotte Sonderbjerg (Age 61)
    Chief Admin. Officer, Sr. VP & Member of the Exec. Board
  • Mr. Peter Rasmussen (Age 53)
    VP of Fin. & Principal Accounting Officer
  • Mr. Timothy J. Lee
    Sr. Director of Investor Relations
  • Mr. Flemming Steen Jensen (Age 61)
    Sr. VP of Product Supply & Quality
  • Dr. Kennett Sprogoe (Age 43)
    Sr. VP and Head of Innovation & Research
  • Dr. Jens Sigurd Okkels Ph.D. (Age 61)
    Sr. VP of Product Devel.













ASND Stock - Frequently Asked Questions

Should I buy or sell Ascendis Pharma A/S stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ASND shares.
View ASND analyst ratings
or view top-rated stocks.

What is Ascendis Pharma A/S's stock price forecast for 2022?

11 brokerages have issued twelve-month price targets for Ascendis Pharma A/S's shares. Their ASND share price forecasts range from $117.00 to $180.00. On average, they predict the company's share price to reach $153.70 in the next twelve months. This suggests a possible upside of 35.5% from the stock's current price.
View analysts price targets for ASND
or view top-rated stocks among Wall Street analysts.

How have ASND shares performed in 2022?

Ascendis Pharma A/S's stock was trading at $134.53 at the beginning of 2022. Since then, ASND stock has decreased by 15.7% and is now trading at $113.46.
View the best growth stocks for 2022 here
.

When is Ascendis Pharma A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our ASND earnings forecast
.

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) released its earnings results on Wednesday, August, 10th. The biotechnology company reported ($1.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.11) by $0.57. The biotechnology company earned $6.51 million during the quarter, compared to the consensus estimate of $7.07 million. Ascendis Pharma A/S had a negative net margin of 2,099.51% and a negative trailing twelve-month return on equity of 48.92%.

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA).

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an initial public offering (IPO) on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ascendis Pharma A/S's stock price today?

One share of ASND stock can currently be purchased for approximately $113.46.

How much money does Ascendis Pharma A/S make?

Ascendis Pharma A/S (NASDAQ:ASND) has a market capitalization of $6.46 billion and generates $9.20 million in revenue each year. The biotechnology company earns $-453,810,000.00 in net income (profit) each year or ($7.89) on an earnings per share basis.

How many employees does Ascendis Pharma A/S have?

The company employs 639 workers across the globe.

How can I contact Ascendis Pharma A/S?

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The official website for the company is www.ascendispharma.com. The biotechnology company can be reached via phone at (457) 022-2244, via email at ir@ascendispharma.com, or via fax at 45-3694-4010.

This page (NASDAQ:ASND) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.